Sanofi K.K. and Taiho Pharmaceutical have announced that the sales of the anticancer agent Jevtana® I.V. Infusion 60 mg will be transferred from Sanofi to Taiho in Japan effective April 1, 2026.
Jevtana is an anticancer agent which was approved and launched in Japan in 2014, indicated for patients with castration-resistant prostate cancer previously treated with a docetaxel-containing regimen. The agent inhibits cell division by promoting tubulin polymerization and stabilizing microtubules, thereby suppressing the proliferation of cancer cells.
On April 1, 2026, Taiho will assume responsibility for the sales and marketing, and medical information activities for Jevtana in Japan, while Sanofi will continue to be the marketing authorization holder and will also continue to manufacture the product.
